epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Arginine vasopressin deficiency or resistance (Diabetes insipidus)

OVERVIEW

  • Highlights & Basics
  • Images

DIAGNOSIS

  • Diagnostic Approach
  • Risk Factors
  • History & Exam
  • Tests
  • Differential Diagnosis
  • Criteria
  • Screening

TREATMENT

  • Tx Approach
  • Tx Options
  • Emerging Tx
  • Prevention

FOLLOW-UP

  • Overview
  • Complications

REFERENCES

  • Citations
  • Guidelines
  • Credits

PATIENT RESOURCES

  • Patient Instructions

Highlights & Basics

AAFont SizeShareMore Information
Key Highlights
  • Arginine vasopressin deficiency (AVP-D; previously known as central diabetes insipidus) or resistance (AVP-R; previously known as nephrogenic diabetes insipidus) are disorders characterized by polydipsia, polyuria, and formation of inappropriately hypotonic (dilute) urine due to renal water loss.

  • AVP-D occurs due to reduced synthesis or release of AVP from the hypothalamo-pituitary axis. AVP-R occurs due to renal insensitivity to AVP.

  • Recognized risk factors for AVP-D include pituitary surgery, craniopharyngioma, infiltrative pituitary stalk lesions, traumatic brain injury, subarachnoid hemorrhage, congenital hypothalamo-pituitary defects, autoimmune disorders, and Wolfram syndrome (also called DIDMOAD [diabetes insipidus, diabetes mellitus, optic atrophy, and deafness] syndrome). Risk factors for AVP-R include lithium therapy, chronic kidney disease, and chronic hypercalcemia or hypokalemia. Genetic mutations are responsible for inherited forms of both types.

  • Both AVP-D and AVP-R may be associated with hypernatremia, and this may present as a medical emergency. Significant hypernatremia usually only occurs in these conditions in association with adipsia (loss of thirst perception) or impaired access to free water.

  • Treatment goals are correction and stabilization of water deficit and electrolyte balance, together with reduction in symptoms of excessive urinary water loss and thirst. In AVP-D, the synthetic AVP analog desmopressin (also known as DDAVP) is the treatment of choice. The mainstay of treatment for AVP-R is adequate fluid intake to match output and insensible losses. Salt restriction and diuretics may help reduce polyuria.

Quick Reference

  • History & Exam

    • Key Factors

      • Other Factors

        More information...
      • Diagnostics Tests

          More information...
        • Treatment Options

            More information...

          Definition

          Epidemiology

          Etiology

          Pathophysiology

          content by BMJ Group
          Last updated

          Images

          • Vasopressin: gene structure and post-translational processing

            Vasopressin: gene structure and post-translational processing

          • Physiology of AVP and thirst

            Physiology of AVP and thirst

          Citations

            Key Articles

            • Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers. 2019 Aug 8;5(1):54.[Abstract]

            • Tomkins M, Lawless S, Martin-Grace J, et al. Diagnosis and management of central diabetes insipidus in adults. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2701-15.[Abstract][Full Text]

            • Kavanagh C, Uy NS. Nephrogenic diabetes insipidus. Pediatr Clin North Am. 2019 Feb;66(1):227-34.[Abstract]

            • Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015 Oct;11(10):576-88.[Abstract]

            • Knepper MA, Kwon TH, Nielsen S. Molecular physiology of water balance. N Engl J Med. 2015 Apr 2;372(14):1349-58.[Abstract]

            Other Online Resources

            • NDI Foundation (DIF)
            • NIDDK: diabetes insipidus
            • Pituitary Foundation (UK): AVP-Deficiency (Diabetes insipidus)

            Referenced Articles

            • 1. Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers. 2019 Aug 8;5(1):54.[Abstract]

            • 2. Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. J Clin Endocrinol Metab. 2022 Dec 17;108(1):1-3.[Abstract][Full Text]

            • 3. Tomkins M, Lawless S, Martin-Grace J, et al. Diagnosis and management of central diabetes insipidus in adults. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2701-15.[Abstract][Full Text]

            • 4. Adams NC, Farrell TP, O'Shea A, et al. Neuroimaging of central diabetes insipidus - when, how and findings. Neuroradiology. 2018 Oct;60(10):995-1012.[Abstract]

            • 5. Kavanagh C, Uy NS. Nephrogenic diabetes insipidus. Pediatr Clin North Am. 2019 Feb;66(1):227-34.[Abstract]

            • 6. Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can. 2010 Mar;32(3):225-31.[Abstract]

            • 7. Weiner A, Vuguin P. Diabetes Insipidus. Pediatr Rev. 2020 Feb;41(2):96-99.[Abstract][Full Text]

            • 8. Di Iorgi N, Napoli F, Allegri AE, et al. Diabetes insipidus - diagnosis and management. Horm Res Paediatr. 2012;77(2):69-84.[Abstract][Full Text]

            • 9. Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009 May;5(5):270-6.[Abstract]

            • 10. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015 Oct;11(10):576-88.[Abstract]

            • 11. Ananthakrishnan S. Diabetes insipidus during pregnancy. Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):305-15.[Abstract]

            • 12. Lindsay RS, Seckl JR, Padfield PL. The triple-phase response - problems of water balance after pituitary surgery. Postgrad Med J. 1995 Jul;71(837):439-41.[Abstract][Full Text]

            • 13. Ghirardello S, Hopper N, Albanese A, et al. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:413-21.[Abstract]

            • 14. Smith D, Finucane F, Phillips J, et al. Abnormal regulation of thirst and vasopressin secretion following surgery for craniopharyngioma. Clin Endocrinol (Oxf). 2004 Aug;61(2):273-9.[Abstract]

            • 15. Agha A, Thornton E, O'Kelly P, et al. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab. 2004 Dec;89(12):5987-92.[Abstract][Full Text]

            • 16. Agha A, Sherlock M, Phillips J, et al. The natural history of post-traumatic neurohypophysial dysfunction. Eur J Endocrinol. 2005 Mar;152(3):371-7.[Abstract][Full Text]

            • 17. Donadieu J, Rolon MA, Thomas C, et al; French LCH Study Group. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr. 2004 Mar;144(3):344-50.[Abstract]

            • 18. Pal R, Rai A, Vaiphei K, et al. Intracranial germinoma masquerading as secondary granulomatous hypophysitis: a case report and review of literature. Neuroendocrinology. 2019 Jul 4 [Epub ahead of print].[Abstract]

            • 19. Sirinvaravong S, Vibhatavata P, Chunharojrith P, et al. Diabetes insipidus and panhypopituitarism as a first presentation of silent adenocarcinoma of lung: a case report and literature review. BMC Endocr Disord. 2019 Oct 29;19(1):114.[Abstract][Full Text]

            • 20. Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM. 2003 Aug;96(8):553-61.[Abstract][Full Text]

            • 21. Santana MF, João GA, Lacerda MV, et al. Diabetes insipidus secondary to tuberculous meningoencephalitis with hypothalamic involvement extending to the hypophysis: a case report. Rev Soc Bras Med Trop. 2018 Nov-Dec;51(6):865-7.[Abstract][Full Text]

            • 22. Domiciano DS, de Carvalho JF, Macedo AR, et al. Central diabetes insipidus induced by tuberculosis in a rheumatoid arthritis patient. Acta Reumatol Port. 2010 Apr-Jun;35(2):232-5.[Abstract][Full Text]

            • 23. Bando H, Iguchi G, Fukuoka H, et al. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol. 2013 Dec 21;170(2):161-72.[Abstract][Full Text]

            • 24. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med. 2000 Oct 5;343(14):998-1007.[Abstract][Full Text]

            • 25. Liu W, Hou J, Liu X, et al. Causes and follow-up of central diabetes insipidus in children. Int J Endocrinol. 2019 Mar 27;2019:5303765.[Abstract][Full Text]

            • 26. Di Iorgi N, Allegri AE, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014 Apr;99(4):1264-72.[Abstract]

            • 27. Schaefers J, Cools M, De Waele K, et al. Clinical presentation and outcome of children with central diabetes insipidus associated with a self-limited or transient pituitary stalk thickening, diagnosed as infundibuloneurohypophysitis. Clin Endocrinol (Oxf). 2017 Aug;87(2):171-6.[Abstract][Full Text]

            • 28. Pivonello R, De Bellis A, Faggiano A, et al. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. J Clin Endocrinol Metab. 2003 Apr;88(4):1629-36.[Abstract][Full Text]

            • 29. Canton A, Simo R, Mesa J, et al. Central diabetes insipidus: a complication of herpes simplex encephalitis. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):325-6.[Abstract][Full Text]

            • 30. Franco-Paredes C, Evans J, Jurado R. Diabetes insipidus due to Streptococcus pneumoniae meningitis. Arch Intern Med. 2001 Apr 23;161(8):1114-5.[Abstract]

            • 31. Hannon MJ, Finucane FM, Sherlock M, et al. Clinical review: disorders of water homeostasis in neurosurgical patients. J Clin Endocrinol Metab. 2012 May;97(5):1423-33.[Abstract][Full Text]

            • 32. Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypernatraemia. NDT Plus. 2009 Oct;2(5):339-46.[Abstract][Full Text]

            • 33. Faje AT, Nachtigall L, Wexler D, et al. Central diabetes insipidus: a previously unreported side effect of temozolomide. J Clin Endocrinol Metab. 2013 Oct;98(10):3926-31.[Abstract][Full Text]

            • 34. Misgar RA, Rasool A, Wani AI, et al. Central diabetes insipidus (Infundibuloneuro hypophysitis): a late complication of COVID-19 infection. J Endocrinol Invest. 2021 Dec;44(12):2855-6.[Full Text]

            • 35. Menotti S, di Filippo L, Terenzi U, et al. Hypophysitis in COVID-19: a systematic review. Pituitary. 2024 Dec;27(6):874-88.[Abstract]

            • 36. Jiao T, Huang Y, Sun H, et al. Research progress of post-acute sequelae after SARS-CoV-2 infection. Cell Death Dis. 2024 Apr 11;15(4):257.[Abstract][Full Text]

            • 37. Taieb A, Nassim BHS, Asma G, et al. The growing understanding of the pituitary implication in the pathogenesis of long COVID-19 syndrome: a narrative review. Adv Respir Med. 2024 Feb 14;92(1):96-109.[Abstract][Full Text]

            • 38. Chang MY, Lin JL. Central diabetes insipidus following carbon monoxide poisoning. Am J Nephrol. 2001 Mar-Apr;21(2):145-9.[Abstract]

            • 39. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46.[Abstract]

            • 40. Werny D, Elfers C, Perez FA, et al. Pediatric central diabetes insipidus: brain malformations are common and few patients have idiopathic disease. J Clin Endocrinol Metab. 2015 Aug;100(8):3074-80.[Abstract][Full Text]

            • 41. Rigoli L, Bramanti P, Di Bella C, et al. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018 May;83(5):921-9.[Abstract][Full Text]

            • 42. Pallotta MT, Tascini G, Crispoldi R, et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med. 2019 Jul 23;17(1):238.[Abstract][Full Text]

            • 43. Ott M, Forssén B, Werneke U. Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. Ther Adv Psychopharmacol. 2019;9:2045125319836563.[Abstract][Full Text]

            • 44. Jacob AT, Kumar AH, Halivana G, et al. Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA adverse event reporting system database. Br J Clin Pharmacol. 2024 Aug;90(8):1804-10.[Abstract][Full Text]

            • 45. Milano S, Carmosino M, Gerbino A, et al. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An update. Int J Mol Sci. 2017 Nov 10;18(11):E2385.[Abstract][Full Text]

            • 46. Lindheimer MD, Davison JM. Osmoregulation, the secretion of arginine vasopressin and its metabolism during pregnancy. Eur J Endocrinol. 1995 Feb;132(2):133-43.[Abstract]

            • 47. Ananthakrishnan S. Gestational diabetes insipidus: Diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2020 Sep;34(5):101384.[Abstract][Full Text]

            • 48. Knepper MA, Kwon TH, Nielsen S. Molecular physiology of water balance. N Engl J Med. 2015 Apr 2;372(14):1349-58.[Abstract]

            • 49. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):471-503.[Abstract]

            • 50. Christ-Crain M. Vasopressin and copeptin in health and disease. Rev Endocr Metab Disord. 2019 Sep;20(3):283-94.[Abstract]

            • 51. Brooks EK, Inder WJ. Disorders of salt and water balance after pituitary surgery. J Clin Endocrinol Metab. 2022 Dec 17;108(1):198-208.[Abstract][Full Text]

            • 52. Yamamoto M, Iguchi G, Bando H, et al. Autoimmune pituitary disease: new concepts with clinical implications. Endocr Rev. 2020 Apr 1;41(2):bnz003.[Abstract][Full Text]

            • 53. Mishra G, Chandrashekhar SR. Management of diabetes insipidus in children. Indian J Endocrinol Metab. 2011 Sep;15 Suppl 3(suppl3):S180-7.[Abstract][Full Text]

            • 54. Baldeweg SE, Ball S, Brooke A, et al; Society for Endocrinology Clinical Committee. Society for Endocrinology clinical guidance: inpatient management of cranial diabetes insipidus. Endocr Connect. 2018 Jul;7(7):G8-11.[Abstract][Full Text]

            • 55. Adrogué HJ, Madias NE. Hypernatremia. N Engl J Med. 2000 May 18;342(20):1493-9.[Abstract]

            • 56. Fleseriu M, Christ-Crain M, Langlois F, et al. Hypopituitarism. Lancet. 2024 Jun 15;403(10444):2632-48.[Abstract]

            • 57. Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome - revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011 May;96(5):1506-15.[Abstract][Full Text]

            • 58. Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018 Aug 2;379(5):428-39.[Abstract][Full Text]

            • 59. Timper K, Fenske W, Kühn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J Clin Endocrinol Metab. 2015 Jun;100(6):2268-74.[Abstract][Full Text]

            • 60. Refardt J, Vogt DR, Christ-Crain M. Arginine or hypertonic saline-stimulated copeptin to diagnose AVP deficiency. Reply. N Engl J Med. 2024 Jan 18;390(3):289-90.

            • 61. Shin JH, Lee HK, Choi CG, et al. MR imaging of central diabetes insipidus: a pictorial essay. Korean J Radiol. 2001 Oct-Dec;2(4):222-30.[Abstract]

            • 62. Tudor RM, Thompson CJ. Posterior pituitary dysfunction following traumatic brain injury: review. Pituitary. 2019 Jun;22(3):296-304.[Abstract]

            • 63. Garrahy A, Moran C, Thompson CJ. Diagnosis and management of central diabetes insipidus in adults. Clin Endocrinol (Oxf). 2019 Jan;90(1):23-30.[Abstract][Full Text]

            • 64. Expert Panel on Neurologic Imaging; Burns J, Policeni B, et al. ACR appropriateness criteria(®) neuroendocrine imaging. J Am Coll Radiol. 2019 May;16(5s):S161-73.[Abstract][Full Text]

            • 65. American College of Radiology. ACR appropriateness criteria: neuroendocrine imaging. 2018 [internet publication].[Full Text]

            • 66. The Royal Children's Hospital Melbourne. Diabetes insipidus. Mar 2011 [internet publication].[Full Text]

            • 67. Baylis PH, Cheetham T. Diabetes insipidus. Arch Dis Child. 1998 Jul;79(1):84-9.[Abstract][Full Text]

            • 68. Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 1976 Mar 4;294(10):507-11.[Abstract][Full Text]

            • 69. Toumba M, Stanhope R. Morbidity and mortality associated with vasopressin analogue treatment. J Pediatr Endocrinol Metab. 2006 Mar;19(3):197-201.[Abstract]

            • 70. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999 Dec;21(6):449-56.[Abstract]

            • 71. Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 Nov;101(11):3888-921.[Abstract][Full Text]

            • 72. Sharma S, Ashton E, Iancu D, et al. Long-term outcome in inherited nephrogenic diabetes insipidus. Clin Kidney J. 2019 Apr;12(2):180-7.[Abstract][Full Text]

            • 73. Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2004 Mar;19(3):608-13.[Abstract][Full Text]

            • 74. Crowley RK, Sherlock M, Agha A, et al. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf). 2007 Apr;66(4):475-82.[Abstract]

            • 75. Grant PJ, Tate GM, Hughes JR, et al. Does hypernatremia promote thrombosis? Thromb Res. 1985 Nov 1;40(3):393-9.[Abstract]

            • 76. Juul KV, Schroeder M, Rittig S, et al. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients. J Clin Endocrinol Metab. 2014 Jun;99(6):2181-7.[Abstract][Full Text]

            • 77. National Organization for Rare Disorders. Nephrogenic diabetes insipidus. Jun 2023 [internet publication].[Full Text]

            • 78. Barbot M, Ceccato F, Zilio M, et al. Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. Pituitary. 2018 Feb;21(1):50-5.[Abstract]

          Have feedback?
          Tell us about your experience
          epocrates logo

          Sign in to access our clinical decision support tools

          Sign inCreate Account
          Download Epocrates from the App StoreDownload Epocrates from the Play Store
          About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
          © 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information